8-K: Avalon GloboCare's Partner to Launch GeeWhiz Catheter Sales, Targeting Multi-Billion Dollar Market

Avalon GloboCare's partner, Laboratory Services MSO, is set to launch sales of the FDA-registered GeeWhiz External Condom Catheter in Q3 2024, targeting the growing male urinary incontinence market.

Summary

• Avalon GloboCare Corp. announced that Laboratory Services MSO, LLC (LSM), in which Avalon owns a 40% interest, will begin selling the GeeWhiz External Condom Catheter in the third quarter of 2024.
• The GeeWhiz device is a patented, FDA-registered male incontinence device already on the market.
• The global male urinary incontinence market was valued at $6.37 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 5.87% from 2023 to 2030.
• The market growth is driven by the increasing prevalence of incontinence, an aging population, and advancements in product technology.
• The GeeWhiz catheter is approved for reimbursement by Medicare and is supported by several private insurance providers.

Sentiment

Score: 7

Explanation: The document is positive due to the launch of a new product in a growing market, with regulatory approvals and reimbursement support. However, it also includes standard risk disclosures, which temper the overall sentiment.

Positives

• The GeeWhiz catheter is a patented, FDA-registered device already on the market.
• The device is approved for reimbursement by Medicare and supported by several private insurance providers, which should facilitate sales.
• The male urinary incontinence market is large and growing, presenting a significant opportunity for LSM and Avalon.
• The device is designed for enhanced comfort, security, and ease of use, potentially improving the quality of life for users.

Risks

• The press release contains forward-looking statements that are subject to risks and uncertainties.
• Actual results may differ materially from those indicated by forward-looking statements due to various factors, including market conditions and competition.
• The company disclaims any obligation to update these forward-looking statements.

Future Outlook

The company anticipates the launch of the GeeWhiz External Condom Catheter in the third quarter of 2024 and expects it to meet a critical need in the market and deliver substantial benefits to patients and healthcare providers.

Management Comments

• David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare, stated that the GeeWhiz External Condom Catheter represents a significant advancement in managing male incontinence.
• Dr. Jin also stated that the anticipated launch of GeeWhiz underscores their commitment to advancing healthcare solutions and expanding their impact in the medical device industry.

Industry Context

The announcement aligns with the broader trend of increasing focus on innovative solutions for age-related health issues, particularly in the medical device sector. The growing market for male urinary incontinence products reflects a need for effective and comfortable management solutions.

Comparison to Industry Standards

• The global male urinary incontinence market is substantial, with a valuation of $6.37 billion in 2022, indicating a significant opportunity for companies like Avalon.
• The projected CAGR of 5.87% from 2023 to 2030 suggests a healthy growth trajectory, which is in line with industry expectations for medical devices addressing age-related conditions.
• Companies like Coloplast and Hollister are major players in the continence care market, and the success of GeeWhiz will depend on its ability to compete with their established products.
• The FDA registration and Medicare reimbursement approval for GeeWhiz are crucial for market penetration, as these are standard requirements for medical devices in the US.

Stakeholder Impact

• Shareholders may view this announcement positively due to the potential for revenue growth.
• Patients with urinary incontinence may benefit from the availability of a new, comfortable, and effective device.
• Healthcare providers may find the device useful in managing their patients' conditions.

Next Steps

• Laboratory Services MSO will launch sales of the GeeWhiz External Condom Catheter in the third quarter of 2024.

Key Dates

Keywords

male incontinence, urinary incontinence, external catheter, medical device, FDA-registered, Medicare reimbursement, healthcare, Avalon GloboCare, Laboratory Services MSO, GeeWhiz